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Abstract
Background: The bed nucleus of the stria terminalis (BNST) is involved in behaviors related to natural reward, drug
addiction and stress. In spite of the emerging role of the endogenous cannabinoid (eCB) system in these behaviors, little is
known about the anatomy and function of this system in the anterolateral BNST (alBNST). The aim of this study was to
provide a detailed morphological characterization of the localization of the cannabinoid 1 (CB1) receptor a necessary step
toward a better understanding of the physiological roles of the eCB system in this region of the brain.
Methodology/Principal Findings: We have combined anatomical approaches at the confocal and electron microscopy level
to ex-vivo electrophysiological techniques. Here, we report that CB1 is localized on presynaptic membranes of about 55% of
immunopositive synaptic terminals for the vesicular glutamate transporter 1 (vGluT1), which contain abundant spherical,
clear synaptic vesicles and make asymmetrical synapses with alBNST neurons. About 64% of vGluT1 immunonegative
synaptic terminals show CB1 immunolabeling. Furthermore, 30% and 35% of presynaptic boutons localize CB1 in alBNST of
conditional mutant mice lacking CB1 mainly from GABAergic neurons (GABA-CB1-KO mice) and mainly from cortical
glutamatergic neurons (Glu-CB1-KO mice), respectively. Extracellular field recordings and whole cell patch clamp in the
alBNST rat brain slice preparation revealed that activation of CB1 strongly inhibits excitatory and inhibitory synaptic
transmission.
Conclusions/Significance: This study supports the anterolateral BNST as a potential neuronal substrate of the effects of
cannabinoids on stress-related behaviors.
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Introduction
The bed nucleus of the stria terminalis (BNST) is a key structure
of the extended amygdala’s network involved in behaviors related
to natural reward, drug addiction and stress [1–7]. Based on cyto
and chemoarchitectonic features, the BNST is composed of several
neuronal nuclei organized in the anterior and posterior divisions
with distinct connectivity and functional implications. Within the
anterior division, we have focused in this study on the anterolateral
area because of the broad connectivity with systems involved in
stress signal processing. This area is innervated densely by the
central nucleus of the amygdala and the amygdalar components of
the main olfactory system (anterior amygdalar, anterior cortical
and postpiriform transition areas, and the anterior basomedial and
posterior basolateral nuclei). It also receives a massive projection
from gustatory and visceral sensory areas of the insular region [8].
Projections from olfactory, gustatory, insular and basolateral,
basomedial and posterior amygdalar regions use glutamate as
neurotransmitter and, thus, they exert an excitatory influence on
their neuronal targets in the anterolateral BNST (alBNST) [8]. On
the other hand, the efferent projections of the alBNST to
autonomic hubs of the hypothalamus and lower brainstem [8]
are organized into somatomotor, central autonomic and neuro-
endocrine systems [9–12] playing a critical role in stress
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neurotransmitter GABA. Indeed, a high neuronal expression of
mRNA coding for glutamic acid decarboxylase (GAD) has been
detected in this region [13]. However, despite the absence of
vesicular glutamate transporter in the alBNST, an excitatory
pathway to the ventral tegmental area originating from neurons
placed in the anteromedial and anteroventral BNST regions has
been reported [14,15].
The endocannabinoid (eCB) system is a versatile modulatory
system expressed widely throughout the central nervous system
(CNS) and as such is involved in numerous fundamental
physiological processes [16,17]. Multiple recent evidence point
toward a role for the eCB system in the behavioral responses to
reward and stress. The implication of this system in reward is well
documented and pharmacological, behavioral and genetic ap-
proaches all indicate its instrumental role in both acute and
prolonged effects of drugs of abuse [18]. Furthermore, the
anatomy and function of CB1 receptors in the BNST linked to
the reward pathway are now beginning to be elucidated [15,19].
Activation of CB1 receptors localized on excitatory presynaptic
boutons of prefrontal infralimbic cortical neurons making synapses
with BNST excitatory projecting neurons to VTA, inhibits VTA
dopamine neurons upon infralimbic cortical stimulation, suggest-
ing a new neuronal circuitry for the actions of cannabinoids
[14,15].
As to stress-related behaviors, the eCB system negatively
modulates the stress-induced activation of hypothalamic-pitui-
tary-adrenal axis [20]. Moreover, inhibition of the degradation or
the reuptake of the two major endocannabinoids (2-arachidonoyl-
glycerol and anandamide) reduces anxiety and depression-like
behaviors in rodent models [21–23].
The presence of CB1 mRNA in projecting neurons to the
anterolateral BNST as well as in intrinsic inhibitory neurons of this
region [24] opens the question about the anatomy and functional
role of the eCB system in the processing information of stress
signals in the anterolateral BNST. In the present study we
combined confocal microscopy, electron microscopy and ex vivo
electrophysiological recordings to investigate the role of CB1
receptors in the rat anterolateral BNST. We found CB1 receptors
localized on presynaptic membranes of excitatory and inhibitory-
like synaptic terminals. Moreover, activation of these receptors by
exogenous agonists strongly inhibited evoked excitatory and
inhibitory post-synaptic currents. Together, the involvement of
presynaptic CB1 in the modulation of excitatory and inhibitory
systems converging onto alBNST neurons projecting to hypotha-
lamic nuclei [25] may be crucial in the regulation of stress
responses.
Results
Immunolocalization of CB1 in the Anterolateral BNST
Confocal and electron microscopy approaches were used to
define the localization of CB1 in the alBNST. CB1 immunoflu-
orescence was observed throughout the anterior division of BNST,
particularly, in the medial (anteroventral, anterodorsal areas) and
lateral groups (anterolateral area) (Fig. 1A). At higher magnifica-
tion, dotty elements and varicose fibers with beaded protrusions
formed a CB1 immunoreactive mesh-like in the neuropil of the
anterolateral area close to the dorsal striatum and adjacent to the
internal capsule (Fig. 1A, A9).
Double preembedding immunoelectron microscopy was used
for the study of the precise localization of CB1 and vGluT1 in the
anterolateral BNST (Fig. 2A, C). About 55% of the presynaptic
boutons immunoreactive for vGluT1 had CB1 silver-intensified
gold particles along their membranes (Figure 3). They contained
round and clear synaptic vesicles and made excitatory asymmet-
rical synapses with postsynaptic dendritic spines and small
dendrites (Fig. 2A, C). Approximately 64% of immunonegative
vGluT1 synaptic terminals showed CB1 immunolabeling (Figure 3;
Fig. 2A). The density of silver-intensified gold particles in
immunopositive and immunonegative vGluT1 synaptic terminals
was 0.80 particles/mm and 0.79 particles/mm, respectively, being
this difference not statistically significant (p.0.05). CB1 immuno-
particles were consistently associated with portions of presynaptic
membranes away from the active zones. CB1 receptors were also
localized in membranes of cross-sectioned thin unmyelinated
axons (Fig. 2A).
Although in situ hybridization studies have shown that the
vGluT1 is the predominant vesicular glutamate transporter in
brain regions of cortical origin projecting to the alBNST, vGluT2
and vGluT3 mRNAs are also present in the basomedial amygdala
and other cortical regions sending axons to the alBNST [29].
Based on this, we evaluated to what extent the presence of CB1 in
vGluT1 + and vGluT1 - synaptic profiles correlates with the
Figure 1. Confocal CB1 immunofluorescence in the anterior division of the rat BNST. In A, intense CB1 labeling was in the anterodorsal
(adBNST), anteroventral (avBNST) and anterolateral (alBNST) BNST around the anterior commissure (ac). In A9, an enlargement of the area framed in A
shows CB1 immunoreactive varicose fibers in alBNST. Str: striatum. Scale bars: A: 200 mm; A9:3 0mm.
doi:10.1371/journal.pone.0008869.g001
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in the alBNST. For this purpose, we used conditional mutant mice
lacking CB1 mainly from cortical glutamatergic neurons (Glu-
CB1-KO mice), and mainly from GABAergic neurons (GABA-
CB1-KO mice) [27,28]. First, we analyzed the subcellular CB1
distribution in alBNST of wild type mice. The pattern was
identical to the rat, with CB1 immunoparticles on presynaptic
boutons making asymmetrical and symmetrical synapses with
small dendrites or dendritic spines (Fig. 2C). CB1 immunoreac-
tivity was not observed in alBNST synapses of CB1 deficient mice
(Fig. 2D). In the conditional GABA-CB1-KO mutants, about 30%
of the presynaptic terminals localized CB1 immunoparticles
(Figure 3) and formed synaptic contacts showing typical ultra-
structural features of excitatory asymmetrical synapses (Fig. 2E).
As to the Glu-CB1-KO mice, CB1 was in approximately 35% of
the synaptic boutons (Figure 3) that were characterized by their
inhibitory-like symmetrical synapses (Fig. 2F).
No specific staining was detected in sections in which the
primary goat anti-CB1 antibodies were replaced by goat serum
(0.069 particles/mm) (not shown).
Cannabinoids Acting at Presynaptic CB1 Inhibit
Glutamatergic Transmission in the Anterolateral BNST
Slice Preparation
The CB1 immunolabeling at vGluT1 + axon terminals forming
asymmetrical synapses and our in vivo observations [15] strongly
suggest the presence of presynaptic CB1 on excitatory afferents
impinging on BNST neurons. We directly tested this possibility
using the slice preparation of the BNST. Both whole cell voltage
clamp and extracellular field recordings were performed in the
alBNST-containing slice preparations.
First, extracellular field recordings were performed to measure
the effects of a CB receptor agonist WIN55,212,2 (WIN-2) on field
Figure 2. Immunolocalization of CB1 and vGluT1 in the rat anterolateral BNST (A, B). Double labeling by combining a preembedding
immunogold (CB1) and an immunoperoxidase (vGluT1) method for electron microscopy. vGluT1 immunoreactive presynaptic axonal terminals
(vGluT1 + ter) making synapses with small dendrites (den) and dendritic spines (sp) localized CB1 immunoparticles at their perisynaptic and
extrasynaptic membranes (white arrows). Observe in A, CB1 immunolabeling (black arrows) in a vGluT1 immunonegative synaptic bouton (vGluT1–
ter); and in B, a vGluT1–synaptic terminal (vGluT1–ter) CB1 immunonegative. Small unmyelinated axons also showed CB1 immunoparticles (asterisks
in A). The CB1 immunolabeled (arrows) synaptic terminals (ter) making synapses with small dendrites (den) and dendritic spines (sp) observed in wild-
type mice (C) disappeared in CB1 2/2 BNST tissue (D). CB1 immunolabeling (arrows) was detected in presynaptic boutons (ter) forming excitatory
asymmetrical synapses with dendritic spines (sp) in the anterolateral BNST of GABA-CB1-KO mutant mice (E). Similarly, CB1 (arrows) was revealed in
inhibitory-like axonal terminals (ter) making symmetrical synapses with small dendrites (den) in the anterolateral BNST of Glu-CB1-KO mutant mice
(F). Scale bars: 0.4 mm.
doi:10.1371/journal.pone.0008869.g002
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of the GABA-A antagonist picrotoxin (100 mM), by stimulating the
internal capsule [19,25]. WIN-2 (5 mM) markedly inhibited the
evoked fEPSP as shown in Fig. 4A. This depression was
completely reversed by the selective CB1 antagonist SR141716A
(Fig. 4A, B; 4 mM) [30], showing the implication of cannabinoid
receptors of the CB1 subtype. No significant effect was observed
when SR141716A was administered alone (Fig. 4B, n=5 paired t
test p=0.2246; ns: p.0.05). We performed full dose-response
curves of the effects of the WIN-2. The CB receptor agonist
inhibited fEPSP in a dose-dependent manner with an EC50 of
25169 nM (Fig. 4C). Thus, the inhibitory effects of WIN-2 can be
attributed to the activation of CB1 receptors in accord with
previous reports [31–33]. As shown in Fig. 4A, the glutamatergic
nature of the extracellular fEPSP was confirmed at the end of each
experiments through the application of the non-NMDA ionotropic
glutamate receptor antagonist DNQX (20 mM), which completely
blocked the synaptic ‘‘N2 component’’ without altering the non-
synaptic ‘‘N1 component’’ [25].
Whole cell voltage clamp recordings (CH3O3SCs-based intra-
cellular medium, holding potential 270 mV) yielded similar
results. Indeed, bath perfusion of WIN-2 (1 mM) inhibited evoked
excitatory postsynaptic currents (EPSCs) as shown in Fig. 5A. This
suppression (Fig. 5B, n=6, paired t test p=0.03; *: p,0.05) was
also reversed by SR141716A (Fig. 5B, n=6, paired t test
p=0.8483; ns: p.0.05).
To functionally assess the origin of the CB1-mediated
depression, the variation of the paired-pulse ratio (PPR) of
excitatory transmission, a presynaptic phenomenon thought to
reflect changes in transmitter release and sensitive to presynaptic
manipulations, was measured during bath application of the CB1
agonist. In agreement with a presynaptic site of action for CB1, the
depression of evoked release induced by the CB receptor agonist
was accompanied by an increase of the PPR (Fig. 5C, n=10,
paired t test p=0.0067; **: p,0.05). Further confirming the
presynaptic origin of the CB1-mediated inhibition, we observed
that the frequency but not the amplitude of spontaneous EPSCs
was reduced following bath perfusion of WIN-2 (Fig. 5D–G,
n=14, Kolmogorov-Smirnov test p,0.0001).
CB1-Mediated Depression at Inhibitory Synapses
Since the anatomical evidence indicate the presence of CB1 in
immunonegative vGluT1 as well as in Glu-CB1-KO synaptic
terminals showing mostly ultrastructural features of inhibitory-
like synapses in the alBNST, we next examined the role of CB1 in
the modulation of the inhibitory synaptic transmission. Afferent
stimulation in the presence of ionotropic glutamate receptor
antagonists elicited IPSCs that were strongly inhibited by bath
perfusion of the CB agonist CP55,940 (Fig. 6A, C; 10 mM).
Between 10 and 20 minutes after CP55,940 evoked IPSCs were
reduced on average to 49.93%+/210.67% (Fig. 5C, n=6, paired
t test p=0.0012; **: p,0.05) of basal value. The suppression
effect of the CB agonist was totally prevented by co-perfusion
with the selective CB1 antagonists 1-(2,4-dichlorophenyl)-5-(4-
iodophenyl)-4-methyl-N-1-piperidinyl-1H-pyrazide-3-carboxa-
mide (AM251; 4 mM, Fig. 5B, C, n=5, paired t test p=0.3549;
ns: p.0.05) demonstrating the implication of cannabinoid
receptors of the CB1 subtype. Thus, the inhibitory synaptic
transmission in the anterolateral BNST is also modulated by CB1
activation.
We compared the paired-pulse ratio (PPR) in order to
determine whether the CP55,940-mediated inhibition was pre-
synaptic or postsynaptic in the inhibitory synapses. CP55,940
modified PPR of evoked IPSCs (Fig. 5D, n=6; paired t test
p=0.0312; *: p,0.05).) indicating a presynaptic localization of
cannabinoid CB1 receptors.
Figure 3. A, Percentages of vGluT1 + and vGluT1 2 synaptic terminals localizing CB1 in the rat anterolateral BNST. 54.52% of the
vGluT1 + and 63.55% of the vGluT1 2 presynaptic boutons localized CB1 silver-intensified gold particles along their membranes. B, Percentages of
CB1 immunopositive synaptic terminals in the anterolateral BNST of wild-type (45.4064.737%), CB1-KO (2.06361.411%), GABA-CB1-KO
(30.9363.309%) and Glu-CB1-KO (33.8363.099) mutant mice. Immunolabeling was negligible in CB1-KO tissue. C, Density of CB1 immunoparticles
in vGluT1 + and vGluT1 2 synaptic membranes after subtraction of background labeling (0.08 particles/mm), and area analyzed in each tissue
condition.
doi:10.1371/journal.pone.0008869.g003
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CB1 Receptors Are Localized in Presynaptic Boutons in
the Anterolateral BNST
The present study reports several findings regarding the
ultrastructural localization and function of CB1 receptors in the
anterolateral BNST, a division of the extended amygdala
particularly involved in stress information processing. We found
that CB1 receptors localize in vGluT1 + and vGluT1–synaptic
terminals, suggesting the distribution of the receptor in excitatory
and also in inhibitory-like boutons impinging on alBNST neurons.
Indeed, previous studies have demonstrated that the alBNST
receives a major excitatory projection from the basolateral
amygdala [11] containing high hybridization signals for CB1
mRNA [24,34], as well as from the insular cortical neurons [11]
expressing low to moderate levels of CB1 mRNA [24]. The recent
anatomical and functional identification of CB1 in excitatory
synaptic terminals from infralimbic cortical neurons restricted to
the anteromedial and anteroventral regions of the BNST [15], did
not overlap with the CB1 synaptic terminal field herein described
in the anterolateral BNST, thus likely serving different functions as
we will discuss later. The anterolateral BNST also receives a
GABAergic projection from the anterior amygdalar and central
amygdaloid nuclei expressing low to high intensities of CB1
mRNA signals [24]. Also, in situ hybridization and immunocyto-
chemistry have demonstrated CB1 in GABAergic BNST neurons
[24,35] which give off local axon collaterals within BNST [13]. All
these pieces of evidence point to a plausible subcellular localization
of CB1 at inhibitory presynatic terminals in the alBNST as
described in other brain regions [36,37]. Indeed, we have
estimated in this study that about 64% of the vGluT1
immunonegative BNST synaptic terminals are CB1 immunore-
active. Also, we have preliminary data (not shown) of a co-
localization of CB1 and green fluorescent protein (GFP) in
alBNST of knock-in mice expressing GFP under the control of the
glutamate decarboxylase 67 (GAD67) promoter [38].
The presence or absence of vGluT1 in synaptic terminals is not
strictly correlated with the excitatory or inhibitory nature of the
pathway. Methodologically, the possibility exits that the vGluT1
antibody gives some weak random background labeling resulting
in false positive terminals, or, alternatively, that many of the very
weakly labeled terminals may had been identified as false-negative
in adjacent sections. Also, in addition to vGluT1, vGluT2 and
vGluT3 mRNAs are expressed in cortical regions projecting to the
alBNST [29]. These concerns prompted us to use conditional
mutant mice lacking CB1 mainly from cortical glutamatergic
neurons (Glu-CB1-KO mice), and mainly from GABAergic
neurons (GABA-CB1-KO mice) [27,28]. In these mutants, CB1
can be distinguished in synaptic terminals fulfilling ultrastructural
features of inhibitory nature (Glu-CB1-KO mice) and excitatory
Figure 4. Pharmacological characterization of the CB1 mediated inhibition in the rat anterolateral BNST. A, Left; typical experiment
(time course) where the CB1 agonist, WIN-2 (5 mM) reduces the fEPSP and the selective CB1 antagonist SR141716A (SR, 4 mM) reverses the WIN-2
induced inhibition. The non-NMDA ionotropic glutamate receptor antagonist DNQX (20 mM) eliminated the fEPSP confirming its synaptic origin.
Right; superimposed traces (average of 20 consecutive fEPSPs taken at the time indicated on the time course) showing the inhibition caused by WIN-2
(b) and its reversion by SR (c). Calibration bars: x: 10 ms, y: 0.2 mV. B, summary of all the experiments performed with WIN-2 and SR: The fEPSP was
98.6460.6590% of baseline in control (n=5), 57.2164.335% (n=5; p=0.0008; ***: p,0.05) with WIN-2 at 60 min, 88.0964.83% (n=5; p=0.0727, ns:
p.0.05) with WIN-2/SR at 120 min, and 105.465.288% (n=5; p=0.2246; ns: p.0.05) 30 min after perfusing only with SR. C, Dose response curve
measured 20 min after beginning WIN-2 application. Each point is expressed as the percentage of inhibition of its basal value. The EC50 for WIN-2 was
251.18+/29.50 nM.
doi:10.1371/journal.pone.0008869.g004
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structures such as the amygdalar components of the main olfactory
system and insular region [8] which do not express CB1 in the
Glu-CB1-KO condition, are not the only excitatory pathways to
alBNST. Indeed, vGluT2 containing-synaptic terminals from the
thalamus and hypothalamus have been demonstrated impinging
on the alBNST [29]. Therefore, it is plausible that the vGluT1–
and Glu-CB1-KO inhibitory-like synaptic terminals localizing
CB1 are overestimated due to the presence of CB1 in excitatory
synaptic terminals of non-cortical origin.
Cannabinoids-Induced Effects on Synaptic Transmission
Are Controlled by Presynaptic CB1 Receptors in the
Anterolateral BNST
We have shown ex-vivo that CB1 activation suppresses both
excitatory and inhibitory synaptic transmission in the alBNST.
CB1 receptor agonists, WIN-2 or CP55,940 depressed EPSC and
IPSCs evoked by afferent stimulation. These suppression effects
were strongly reduced by CB1 antagonists. When SR141716A and
AM251 were administered alone, there was no significant effect
Figure 5. CB1 inhibits glutamatergic synapses in the anterolateral BNST at a presynaptic locus. A, time course of 1 mM WIN-2-induced
inhibition of evoked EPSC normalized to baseline. B, Summary of all experiments performed as described in A: EPSC was 100.667.355% (n=6) of
baseline in control, 58.4665.406% (n=6; p=0.03 t test *: p,0.05) at 60 min after WIN-2 and 103.765.230% (n=6; p=0.8483; ns: p.0.05) at 120 min
after co-perfusion with SR C left, paired-pulse ratio were augmented during WIN-2 perfusion (n=10; paired t test p=0.0065; **: p,0.05). PPR was
calculated with 60 sweeps i.e. 10 min before and 20 min after WIN-2.; right, representative EPSC traces from an alBNST neuron before and after WIN-2
application, average of 30 consecutive traces. Observe that the inhibition of the first EPSC by WIN-2 is larger than the second one. Calibration bars: x:
25 ms, y: 50 pA. D, bath perfusion of WIN-2 did not change the distribution of sEPSCs amplitude (n=14). E, the distribution of the time intervals
between successive sEPSCs in these neurons revealed that the sEPSCs frequency was reduced during WIN-2 application. (Kolmogorov-Smirnov test
p,0.0001). Representative consecutive 2-sec current sweeps from a cell where sEPSCs were recorded in control (F) and 30 min after the start of the
WIN-2 application (G). Calibration bars: x: 250 ms, y: 20 pA.
doi:10.1371/journal.pone.0008869.g005
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alBNST is not tonically active. Taken together, our results indicate
a broad functional enrolment of CB1 receptors distributed in both
excitatory and inhibitory synaptic terminals in the alBNST.
We found that cannabinoids increase the PPR of EPSCs and
IPSCs, consistent with a decrease in release probability. In
agreement with this idea, we further found that a CB receptor
agonist decreases the frequency, but not the amplitude, of sEPSCs.
The localization of CB1 in GABAergic and glutamatergic
presynaptic terminals is well documented [36,38–43], and many
studies in different brain regions have demonstrated that
cannabinoids acting at presynaptic CB1 receptors depress
inhibitory and excitatory synaptic transmission [16,44–47]. But
beyond this, the reported observations herein settle recent
evidence from our laboratories that the activation of CB1
receptors at excitatory synapses by 2-AG and anandamide
generated by separate signals mediates two distinct forms of
short-term (depolarization-supression of excitation) and long-term
(long-term depression) synaptic plasticity in a single anterolateral
BNST neuron [48]. Physiologically, the identification of this eCB-
dependent synaptic plasticity in the anterolateral BNST could be
regarded as a potential neuronal substrate of the effects of
cannabinoids on stress-related behaviors [48]. The contribution of
the presynaptic CB1-mediated modulation of the inhibitory
synaptic transmission to the functional role of the anterolateral
BNST remains to be elucidated.
Behavioral Significance of Cannabinoids Action in the
Anterolateral BNST
The BNST plays a key role in integrating information from
stress input pathways and in turn regulating stress output and
reward pathways. It has been suggested that the BNST acts as an
intermediary for regions of the brain involved in perceiving stress
and regions of the brain producing responses to stress [1,9]. The
ventral subiculum and cortical areas that transmit ‘‘processive’’
stressor information and the noradrenergic projections from the
Figure 6. Activation of presynaptic cannabinoid receptors diminishes GABAA IPSCs recorded in anterolateral BNST neurons. A,
Typical experiment (time course) where the CB1 agonist, CP55,940 (10 mM) inhibited IPSCs. Above traces represent the average of 10 consecutive
EPSCs taken at the times indicated on the time-course graph. B, The inhibitory effects of CP55,940 on evoked IPSCs were blocked by pre-treatment
with the selective CB1 antagonist AM251 (4 mM) in agreement with the involvement of CB1. Above traces represent the average of 10 consecutive
IPSCs taken at the times indicated on the time-course graph. All experiments were conducted in the presence of DNQX 20 mM and APV 50 mm. C,
Summary of all experiments performed as described in A and B: IPSC was 100.163.647% (n=6) of baseline in control, 49.93610.67% (n=6; p=0.0012
t test **: p,0.05) at 60 min after CP55,940 and 92.7167.119% (n=5; p=0.3549; ns: p.0.05) at 120 min after perfusion with AM251. D, Paired-pulse
ratio were augmented during CP55,940 perfusion (n=6; paired t test p=0.0312; *: p,0.05). PPR was calculated with 60 sweeps i.e. 10 min before and
20 min after CP55,940.
doi:10.1371/journal.pone.0008869.g006
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information project to the paraventricular nucleus (PVN) via a
relay in the BNST, as well as via direct projections to the
hypothalamus. Actually, the anterolateral BNST projects to
somatomotor (nucleus accumbens, substantia innominata, ventral
tegmental area, retrorubral area and adjacent midbrain reticular
nucleus), central autonomic (central amygdalar nucleus, dorsal
lateral hypothalamic area, ventrolateral periaqueductal gray,
parabrachial nucleus and nucleus of the solitary tract)
and neuroendocrine (paraventricular and supraoptic nuclei,
hypothalamic visceromotor pattern generator network) systems
[10–12,14].
The interactions between the BNST, PVN and ventral
tegmental area (VTA) are complex, but one prediction would be
that activation of the BNST by processive stressors (i.e., ventral
subiculum and cortical areas) would result in increased output
from BNST to the nucleus accumbens, VTA, PVN and/or the
hypothalamic area surrounding the PVN. However, it is as yet
unclear whether this would have a net excitatory or inhibitory
effect on these regions. For example, while the majority of the
BNST neurons are GABAergic, the demonstration of an
excitatory projection from the anteroventral BNST to the VTA
[14] could result in an increase of dopamine release in the nucleus
accumbens. Thus it is plausible that BNST neurons play a role in
the integration of information leading to adaptive changes in
synaptic responses after administration of drugs of abuse. Indeed,
this brain region plays a critical role in footshock-induced
reinstatement of drug seeking [49–51], as well as morphine
withdrawal-induced conditioned place aversion [52]. On the other
hand, based on animal-wide genetic and pharmacological
manipulations, cannabinoid signaling in the CNS acting through
CB1 is thought to be actively involved also in the dopaminergic
mesolimbic brain reward circuit. Pharmacological [53,54] as well
as genetic disruption [55,56] of CB1 receptor activity elicits
anxiety-like behaviors in rodents, suggestive of the existence of an
intrinsic anxiolytic tone mediated by endogenous cannabinoids.
Our findings may serve as a basis for the interpretation of the
mechanism by which cannabinoid receptors can regulate behav-
ioral anxiety and stress-drug interactions in the BNST.
Materials and Methods
Animal Treatment
The protocols for animal care and use were approved by the
appropriate Committee at the Basque Country University.
Furthermore, the animal experimental procedures were carried
out in accordance with the European Communities Council
Directive of 22 July 2003 (2003/65/CE) and current Spanish
regulations (Real Decreto 1201/2005, BOE 21-10-2005). Great
efforts were made in order to minimize the number and suffering
of the animals used.
Confocal Immunofluorescence
Rats (n=3, Sprague-Dawley 250 g) were deeply anesthetized
with chloral hydrate (400 mg/kg body weight) and were
transcardially perfused at room temperature (RT, 20–25uC) with
phosphate-buffered saline (PBS, 0.1 M, pH 7.4) for 20 seconds,
followed by 500 ml of 4% formaldehyde (freshly depolymerized
from paraformaldehyde) and 0.2% picric acid in 0.1 M phosphate
buffer (PB), pH 7.4, for 10–15 minutes. Then, brains were
removed from the skull and postfixed in 4% formaldehyde for
up to 1 hour at RT. 50 mm-thick coronal sections cut from
alBNST in a vibratome, were washed and blocked in 0.1 M PBS
containing 3% newborn calf serum (NCS), 0.5% Triton X-100
and 0.025% sodium azide for 1 hour at RT. We used polyclonal
goat anti-CB1 antibodies (3 mg/ml in 3% NCS/PBS for 2 days at
4uC; CB1-Go-Af450-1; Frontier Science Co. Ltd; 1-777-12,
Shinko-nishi, Ishikari, Hokkaido, Japan). Slices were then washed
in blocking solution (3% NCS/PBS) and incubated with donkey
anti-goat Alexa Fluor-488 (Molecular Probes, Eugene, OR, USA)
at a working dilution of 1:650 in 3% NCS/PBS for 1 day at 4uC.
Slices were washed again in 0.1 M PBS and then mounted in
Vectashield medium (Vector Laboratories, Burlingame, CA,
USA), coverslipped, and imaged on a laser-scanning confocal
microscope (Olympus Fluoview FV500). Photomicrographs were
taken and presented using Adobe Photoshop (CS, Adobe Systems,
San Jose, CA, USA).
CB1 Immunocytochemistry for Electron Microscopy
Rats (n=5, Sprague-Dawley 250 g) were deeply anesthetized as
described above. In addition, 12 wild-type, Glu-CB1-KO, GABA-
CB1-KO and CB1-KO mice (3 of each condition; [26–28]) were
deeply anesthetized by i.p. injection of a mixture of Nembutal
(5 mg/100 g body weight; Abbott Laboratories Inc., IL, USA) and
urethane (130 mg/100 g body weight; Sigma-Aldrich, St. Louis,
MO, USA). All animals were transcardially perfused with PBS
(0.1 M, pH 7.4) and then fixed by 500 ml of 0.1% glutaraldehyde,
4% formaldehyde and 0.2% picric acid in PBS. Perfusates were
used at 4uC. Tissue blocks were extensively rinsed in 0.1 M PBS
(pH 7.4).
Coronal alBNST vibrosections were cut at 50 mm and collected
in 0.1 M PBS (pH 7.4) at RT. Sections were preincubated in a
blocking solution of 10% bovine serum albumin (BSA), 0.1%
sodium azide and 0.02% saponin prepared in Tris-HCl buffered
saline (TBS, pH 7.4) for 30 minutes at RT. A preembedding
silver-intensified immunogold method and an immunoperoxidase
method were used for the co-localization of CB1 and the vesicular
glutamate transporter 1 (vGluT1) in rat alBNST sections. They
were incubated in primary polyclonal goat anti-CB1 (3 mg/ml)
and guinea pig anti-vGluT1 (1:1,000; Millipore Bioscience
Research Reagents, formerly Chemicon, Temecula, CA, USA)
antibodies both in 10% BSA/TBS containing 0.1% sodium azide
and 0.004% saponin on a shaker for 1 day at RT.
After several washes in 1% BSA/TBS, tissue sections were
incubated in a secondary 1.4 nm gold-labeled rabbit anti-goat IgG
(Fab’ fragment, 1:100, Nanoprobes Inc., Yaphank, NY, USA) for
the detection of CB1, and in a biotinylated donkey anti-guinea pig
IgG (1:200, Jackson ImmunoResearch Inc., Baltimore, Pennsyl-
vania, USA) for the detection of vGluT1, both in 1% BSA/TBS
with 0.004% saponin on a shaker for 4 hours at RT.
alBNST tissue was washed in 1% BSA/TBS and processed by a
conventional avidin-biotin horseradish peroxidase complex meth-
od (ABC; Elite, Vector Laboratories Burlingame, CA, USA).
Tissue was washed in 1% BSA/TBS overnight at 4uC and
postfixed in 1% glutaraldehyde in TBS for 10 minutes at RT.
Following washes in double-distilled water, gold particles were
silver-intensified with a HQ Silver kit (Nanoprobes Inc., Yaphank,
NY, USA) for about 12 minutes in the dark and then washed in
0.1 M PB (pH 7.4). Sections were preincubated subsequently with
0.05% DAB in 0.1 M PB for 5 minutes, incubated by adding
0.01% hydrogen peroxide to the same solution for 5 minutes and
washed in 0.1 M PB for 2 hours at RT. Stained sections were
osmicated (1% OsO4 in 0.1 M PB, pH 7.4, 20 minutes),
dehydrated in graded alcohols to propylene oxide and plastic-
embedded flat in Epon 812. 80 nm ultrathin sections were
collected on mesh nickel grids, stained with uranyl acetate and
lead citrate, and examined in a PHILIPS EM2008S electron
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digital camera coupled to the electron microscope.
Figure compositions were scanned at 500 dots per inch (dpi).
Labeling and minor adjustments in contrast and brightness were
made using Adobe Photoshop (CS, Adobe Systems, San Jose, CA,
USA).
Slice Preparation and Ex-Vivo Electrophysiology
Whole cell patch-clamp and extracellular field recordings were
made from visualized principal pyramidal cells (projecting star
neurons homologous to temporal layer V cortical pyramidal
neurons [13]) in coronal slices of rat alBNST (Sprague-Dawley
250 g), as previously described [25]. In brief, rats were
anesthetized with halothane and decapitated. The brain was
sliced (300 mm) in the coronal plane using a vibratome
(Integraslice, Campden Instruments, UK) and maintained in
physiological saline at 4uC. Slices containing the alBNST were
stored at 32–35uC before being placed in the recording chamber
and superfused (2 ml/min) with artificial cerebrospinal fluid
(ACSF) that contained (in mM): 126 NaCl, 2.5 KCl, 1.2 MgCl2,
2.4 CaCl2, 18 NaHCO3, 1.2 NaH2PO4, and 11 Glucose, and was
equilibrated with 95% O2/5% CO2. All experiments were done at
32–35uC. Isolated excitatory postsynaptic currents (EPSCs) or
inhibitory postsynaptic currents (IPSCs) were evoked pharmaco-
logically by local stimulation within the alBNST and superfusion
of picrotoxin (PTX, 100 mM) to block GABAA receptors or the
glutamate receptor blockers 6,7 dinitroquinoxaline-2,3-dione
(DNQX, 20 mM) and DL-2-amino-5-phosphonovalerate (APV,
50 mM) to isolate GABAergic IPSCs. All drugs were added at the
final concentration to the superfusion medium.
To evoke synaptic currents, stimuli (100–150 msec duration)
were delivered at 0.1 Hz through a glass electrode filled with
ACSF and placed at the border between the internal capsule and
the alBNST [19,25]. Both the EPSC/IPSC area and amplitude
were measured (graphs depict amplitudes).
For extracellular field recordings, the pipette was filled with
ACSF. Both the field excitatory postsynaptic potential (fEPSP)
area and amplitude were measured (graphs depict amplitudes).
The glutamatergic nature of the extracellular fEPSP was
confirmed at the end of the experiments through the application
of the non-NMDA ionotropic glutamate receptor antagonist
DNQX (20 mM), which completely blocked the synaptic N2
component without altering the non-synaptic N1 component.
For whole cell patch-clamp experiments, alBNST principal
neurons were visualized using an upright microscope with infrared
illumination. Recordings were made with whole cell electrodes
containing the following (mM): cesium methane-sulfonate
(CH3O3SCs) 128, NaCl 20, MgCl21, EGTA 1, CaCl2 0.3,
Na
2+-ATP 2, Na
+-GTP 0.3, Glucose 10 buffered with Hepes 10,
pH 7.3, osmolarity 290 mOsm. Electrode resistance was 4–6
MOhms.
A 22 mV hyperpolarizing pulse was applied before each
EPSC/IPSC in order to evaluate the access resistance, and those
experiments in which this parameter changed .20% were
rejected. Access resistance compensation was not ordinarily used
and acceptable access resistance was ,25 MOhms. The potential
reference of the amplifier was adjusted to zero prior to breaking
into the cell. An Axopatch-1D (Axon Instruments, USA) was used
to record the data, which were filtered at 1–2 kHz, digitized at
5 kHz on a DigiData 1200 interface (Axon Instruments, USA) and
collected on a PC using Clampex 9.2 (Axon Instruments, USA)
and analyzed using Clampfit 9.2 (Axon Instruments, USA).
Spontaneous excitatory postsynaptic currents (sEPSCs) were
recorded in the whole cell voltage-clamp configuration using
Axoscope 9.2 (Axon Instruments, USA). sEPSC amplitude and
inter-interval time were detected and analyzed using Clampfit 9.2
(Axon Instruments, USA). For this analysis, a template of sEPSCs
generated from averaging several typical synaptic events was slided
along the data trace one point at a time. At each position, this
template is optimally scaled and offset to fit the data and a
detection criterion is calculated. The detection criterion is the
template-scaling factor divided by the goodness-of-fit at each
position. An event is detected when this criterion exceeds a
threshold and reaches a sharp maximum.
For the estimation of the paired-pulse ratio (PPR), two stimuli
were delivered with a 50 msec interval at stimulus intensity about
40–60% of the one eliciting the maximal response (,0.2 mA). The
PPR of evoked excitatory and inhibitory postsynaptic currents was
calculated by dividing the mean of all 30 EPSC2 or IPSC2 (2nd
evoked responses) amplitudes by the mean of all 30 corresponding
EPSC1 or IPSC1 (1st evoked responses).
Data Analysis and Materials
All values are given as mean 6 S.E.M. For field recording
experiments and patch-clamp experiments, n corresponds to the
number of individual cells analyzed, with at least 4 animals
included in each condition. When two means were compared
considering the relation between before and after drug application,
statistical significance of their difference was assessed using two-
tailed paired Student’s t tests. Kolmogorov-Smirnov test was used
for the statistical comparison of the cumulative distributions. All
statistical tests were performed with Graph Pad PRISM (version
4.0; Graph Pad Software Inc. San Diego, CA, USA) and Kyplot
v2.0 beta 13 (Developed by Koichi Yoshioka; Tokyo, Japan).
The fitting of concentration response curves were calculated
according to y={ymax2ymin/1+ (x/EC50)n}+ ymin (where ymax=
response in the absence of agonist, ymin=response remaining in
presence of maximal agonist concentration, x=concentration,
EC50=concentration of agonist producing 50% of the maximal
response and n=slope) with Kaleidagraph software (Abelbeck
Software, USA).
Quantitative Analysis of CB1 in vGluT1 + and vGluT1–
Synaptic Terminals
alBNST sections from 3 rats processed for the co-localization of
CB1 and vGluT1 with preembedding immunocytochemistry were
used for quantitative analysis. 50-mm-thick alBNST sections from
each animal showing good and reproducible DAB immunoreac-
tion and silver-intensified gold particles were cut at 80 nm. Image-
J (version 1.36) was used to measure the membrane length.
Electron micrographs (10,000–25,000X) were taken from grids
(132 mm side) containing DAB immunodeposits; all of them
showed a similar DAB labeling intensity indicating that selected
areas were at the same depth. Furthermore, to avoid false
negatives, only ultrahin sections in the first 1.5 mm from the
surface of the tissue block were examined. Positive labeling was
considered if at least one immunoparticle was within approxi-
mately 30 nm from the plasmalemma. Metal particles on
membranes and positive immunoreactive profiles were visualized
and counted. Density of immunoparticles were averaged from
different samples and presented as mean 6 S.E.M. Group
differences were compared by unpaired Student’s t test (two-
sided); p,0.05. The level of background labeling (0.08 particles/
mm) was subtracted from the density of immunoparticles in
synaptic terminals.
Percentages of vGluT1 + and vGluT1–synaptic terminals with
CB1 were analyzed and displayed using a statistical software
CB1R in BNST Synapses
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USA).
Drugs
Picrotoxin, and CP55,940 from SIGMA (St. Quentin Fallavier,
France), DNQX, AM251, APV and WIN55,212,2 from Tocris
(Bristol, UK). SR141716A was a generous gift from Sanofi-
Recherche (Montpellier, France). Other chemicals were from the
highest commercial grade available.
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